Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 1,521–1,530 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1521

    Medicine slug
    tizanidine
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    125
    Source count
    124
    Agreement rate
    1
    Recorded readings

    1. 40%

      Numeric value
      40
      Unit
      %
      Source records
      124

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 124 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a7b9b9a-9bf9-0b37-e063-6294a90a1c39 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2f4e117-0318-4bbd-aaa7-fab803714f21 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:247ae1f4-6ec8-4e34-aae4-13495d8f64e5 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67b2af93-92c9-4c33-8fa0-548bfcc9c538 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc96ee6-c99b-7283-e053-2a95a90ad14d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f87e30ce-a60a-41e3-b5d6-7e2966143961 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a3fa9c69-4baf-44f5-bac4-a19c34b0e1cb (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ac00d59-bb80-4530-afe7-90e04a2130b2 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22ea819a-2aaa-44e0-a350-258541b11220 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24d8b33f-d1fb-4b4a-afbe-e2e7134dce29 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f460275-565f-4737-a3df-bf80b9acc268 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cfd52c0c-a7c2-e23d-e053-2a95a90abbd1 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9833a1b8-f530-4a06-bc77-7d11b6e94c65 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26f8f233-5dc2-0013-e063-6394a90ab0f5 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81501cb1-0a76-4bd0-8eee-dbd1e4a0b69f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eed74219-9d4a-fecd-1bb9-ad6c01ad3e9d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4659df31-8b89-4eff-9d86-7b7e38de416b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a91884a-39c3-f7ac-e063-6394a90ade14 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:73269d77-16b5-4787-9a7d-1b8688623436 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c2bdad9-74a5-8508-e063-6294a90aac7f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f4889d1-1387-4c90-9b76-00beda3c1683 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac897a5a-677b-4a6e-abb1-b810470200fc (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a275f9-de6b-ee63-e063-6294a90aba28 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:99cc8f5f-b947-4ddc-99b6-1e4cef09b717 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb8b01b3-bcec-4762-9d67-0db018ef6b22 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82084f4e-00d0-c298-c13a-88a6c0860b02 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe2f5064-0b7c-d03d-e053-6294a90a9604 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03fa03a6-fd05-4f17-872a-3c123330935d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae9b6808-632f-4204-8581-bf146dcab69f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32c3be66-5398-425c-ac65-e57ba819bb43 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b353cdb8-75fa-7e3c-e053-2a95a90ada58 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:043d9e51-bfa2-4add-9058-5ece332f7e99 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ebccdb33-2b3c-4071-9765-8d95bcbc9b5f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0e4eb26-6733-4df6-bb3c-86bf4d976f42 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c993e3c-ee52-45a7-be39-60eaac7a1092 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dd09a0d-a782-1d6d-a552-b71e5bcbf2fe (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e13b111a-25b7-4fdd-a102-30f2996722f3 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72f25135-1333-4e52-83f5-7df7d90e68bb (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea242c7d-b101-4197-8e65-b2b079e3b2b6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf77e63c-a62a-43fc-8705-0558925e04e8 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89105a78-badb-469e-966e-195fa3a53f0a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2353d09-3cb4-486e-8ae7-29339c1ba76b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d9a2492-d914-f87b-e063-6394a90a38c6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8288ccd-6c66-415e-a06b-758971afe9a0 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0bdc188d-b895-acbc-e063-6294a90acd68 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180985f0-3fbd-4868-a826-b84101618a03 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:21b7c8a8-ee07-a204-e063-6394a90a285b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b88c338-c0b7-4c08-bef6-a4ffc2f25df7 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49adcfc8-3b1d-7f7e-e063-6294a90a361e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5460dbf8-b30d-db94-e063-6394a90a5553 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd3bf952-50b1-4d50-9073-57fd6888053b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20424d92-5ca1-4114-bc51-1f07c3bed6be (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76dc85bd-3cde-4940-a99b-663b70bf9f54 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d2961d1c-5de2-0a2b-e053-2995a90ad2fc (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01c0d3d3-2373-a1b7-822a-80a66291a248 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:acc8f9f6-ceb6-0505-8f11-fd7e1f105af3 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f39499a-98cf-4d13-9b07-ccb5c22e43c8 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b694225c-1fa9-4726-89a6-fd3f87084248 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:047c67cd-7a63-49c9-b100-71651d3537ba (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14bcfbac-8f6a-42af-b3a4-ba10d99f2468 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59084f59-9a9b-49f0-a9f4-27f3eab9a228 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc90292-c6bf-2d96-e053-2995a90abf00 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3670f9e3-988d-48e6-9df0-d403d699e08a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f8a5b21-4adb-4f2c-91ae-bc33c3810752 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff7a82ea-c03c-44f6-9b15-468cb8d15a9c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b254a0f4-efb1-4874-ae45-1dc5fe316964 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52830423-0430-410e-93af-169dc11b3565 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6b4486f-e847-64ee-e053-2995a90a855a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45de30ce-959f-4e2e-a974-6f90568139c9 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8d0b2b22-e1df-4ad5-92e6-f9a369108e4b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59d83e3a-5e44-d8d0-e063-6294a90aa65a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b14bd166-9f53-4f2e-be05-c447af04ef69 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5b7b4721-e6fa-4586-ac40-091ad363ee85 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a5b6614-038f-4e5b-9543-0497872c7882 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af73c6ab-6c1c-94d1-e053-2a95a90a4e3c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef7673f4-e0c1-4d79-af36-2f2ed2cc28f7 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:615dfd5c-125a-40e2-a6da-afacde305282 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eeb18068-75c8-42d0-a006-1b134648333f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da31fbeb-3781-5e75-e053-2a95a90adb73 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a2cf456-58c5-c26d-e063-6294a90a0b24 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25db7cc0-604c-3d6b-e063-6394a90a337f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9bcc7f09-d2b5-4602-aaf3-5410b55ce275 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9678a98e-4aab-4d87-b5e1-37c3109e378e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30caf3b3-8c1b-268e-e063-6294a90a3c8a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19cf46b5-d8dc-44cb-83d6-bacea0870dbe (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51da17a0-63d2-44fb-a79d-a3bee862e028 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e13292b0-9858-4405-8787-a2392d1b6d75 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:433ac98f-ac22-44ad-a8b4-5db5560b9d0f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63b7eba3-6dea-4d89-bc42-7e965ae9795d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fdf4f09d-4537-a438-e053-6394a90a573d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:146c853c-99a8-4bf3-b1e3-be6876abe6ff (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07b8db58-d037-477e-a62f-025e8a5afcb4 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:308d2fdc-6136-4e75-95d3-342497add66c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e97c1ba-8171-4707-98ee-61afed75daac (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7470959-8943-215b-e053-2a95a90a7878 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3b8d863-d13d-467c-97bf-5db9708036db (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81385ce2-1d82-4987-8e18-83c823e10b99 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6439a7ef-1b22-4fa1-9be3-eedd3cd24191 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c46c7aa3-69db-82dc-e053-2995a90ac251 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d127a0b-b182-4c8a-91a3-311cc936fd4c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f32f399f-42af-f0ba-e053-2a95a90a8c2e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fefe8332-32eb-4b81-978f-b23b334d7d57 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fd932fb-033c-4774-ac09-c823db8f9739 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee3e9813-a738-46d1-9c05-c931aee1495c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ade0c7-4bf0-54d4-e063-6294a90a8b17 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6dd9946f-b2a4-1732-e053-2a91aa0a648f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:492c99bd-2cd0-43be-bd70-800b739b7e83 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b68a9f81-7138-48cf-b987-b8d284e8105a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2788942d-87fa-e514-e063-6294a90a0971 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9ba9023-0c3f-4c9b-ba8e-d39d23bf35d6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26cffb1f-21a0-017f-e063-6394a90afb1a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58c10b87-004e-4d2d-b5c1-b353c2cd071f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29750221-497e-4747-a9b8-12a0c2236eae (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e19f83b8-8c59-415c-a744-7473d46ab0ca (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e94aa8b1-74ed-46b7-94c5-53d5d5630be6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a42f3479-f2c2-8214-d547-c5cae9bfed1e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7d5dce0-f8a2-404d-9e87-e2235f5d3268 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd16a25c-67b6-ae6c-e053-6394a90aeee0 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4009c6cb-c183-2165-e063-6294a90aed78 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8278b4e-cca2-4880-8924-c8202ce084d6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60c27d35-7349-4fc6-86ad-70fffdbe3e08 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bbc81e5-ad3e-496b-908f-e6f500f6ad7e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f041e5f7-c138-4622-98bf-881f9a649a26 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d24e0cda-a22f-404f-b861-f85090cef099 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism.

  2. Projected row 1522

    Medicine slug
    tizanidine
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    125
    Source count
    124
    Agreement rate
    0.572581
    Recorded readings

    1. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      71

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 71 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a7b9b9a-9bf9-0b37-e063-6294a90a1c39 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:247ae1f4-6ec8-4e34-aae4-13495d8f64e5 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67b2af93-92c9-4c33-8fa0-548bfcc9c538 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc96ee6-c99b-7283-e053-2a95a90ad14d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f87e30ce-a60a-41e3-b5d6-7e2966143961 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24d8b33f-d1fb-4b4a-afbe-e2e7134dce29 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f460275-565f-4737-a3df-bf80b9acc268 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26f8f233-5dc2-0013-e063-6394a90ab0f5 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81501cb1-0a76-4bd0-8eee-dbd1e4a0b69f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eed74219-9d4a-fecd-1bb9-ad6c01ad3e9d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4659df31-8b89-4eff-9d86-7b7e38de416b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a91884a-39c3-f7ac-e063-6394a90ade14 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:73269d77-16b5-4787-9a7d-1b8688623436 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c2bdad9-74a5-8508-e063-6294a90aac7f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a275f9-de6b-ee63-e063-6294a90aba28 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb8b01b3-bcec-4762-9d67-0db018ef6b22 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82084f4e-00d0-c298-c13a-88a6c0860b02 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe2f5064-0b7c-d03d-e053-6294a90a9604 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03fa03a6-fd05-4f17-872a-3c123330935d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae9b6808-632f-4204-8581-bf146dcab69f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b353cdb8-75fa-7e3c-e053-2a95a90ada58 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:043d9e51-bfa2-4add-9058-5ece332f7e99 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72f25135-1333-4e52-83f5-7df7d90e68bb (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea242c7d-b101-4197-8e65-b2b079e3b2b6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0bdc188d-b895-acbc-e063-6294a90acd68 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180985f0-3fbd-4868-a826-b84101618a03 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:21b7c8a8-ee07-a204-e063-6394a90a285b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd3bf952-50b1-4d50-9073-57fd6888053b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20424d92-5ca1-4114-bc51-1f07c3bed6be (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76dc85bd-3cde-4940-a99b-663b70bf9f54 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d2961d1c-5de2-0a2b-e053-2995a90ad2fc (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b694225c-1fa9-4726-89a6-fd3f87084248 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14bcfbac-8f6a-42af-b3a4-ba10d99f2468 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc90292-c6bf-2d96-e053-2995a90abf00 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3670f9e3-988d-48e6-9df0-d403d699e08a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f8a5b21-4adb-4f2c-91ae-bc33c3810752 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff7a82ea-c03c-44f6-9b15-468cb8d15a9c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b254a0f4-efb1-4874-ae45-1dc5fe316964 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59d83e3a-5e44-d8d0-e063-6294a90aa65a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5b7b4721-e6fa-4586-ac40-091ad363ee85 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a5b6614-038f-4e5b-9543-0497872c7882 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af73c6ab-6c1c-94d1-e053-2a95a90a4e3c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef7673f4-e0c1-4d79-af36-2f2ed2cc28f7 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25db7cc0-604c-3d6b-e063-6394a90a337f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9bcc7f09-d2b5-4602-aaf3-5410b55ce275 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51da17a0-63d2-44fb-a79d-a3bee862e028 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e13292b0-9858-4405-8787-a2392d1b6d75 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fdf4f09d-4537-a438-e053-6394a90a573d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07b8db58-d037-477e-a62f-025e8a5afcb4 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7470959-8943-215b-e053-2a95a90a7878 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3b8d863-d13d-467c-97bf-5db9708036db (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81385ce2-1d82-4987-8e18-83c823e10b99 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6439a7ef-1b22-4fa1-9be3-eedd3cd24191 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c46c7aa3-69db-82dc-e053-2995a90ac251 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f32f399f-42af-f0ba-e053-2a95a90a8c2e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fefe8332-32eb-4b81-978f-b23b334d7d57 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ade0c7-4bf0-54d4-e063-6294a90a8b17 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6dd9946f-b2a4-1732-e053-2a91aa0a648f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:492c99bd-2cd0-43be-bd70-800b739b7e83 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b68a9f81-7138-48cf-b987-b8d284e8105a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2788942d-87fa-e514-e063-6294a90a0971 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26cffb1f-21a0-017f-e063-6394a90afb1a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58c10b87-004e-4d2d-b5c1-b353c2cd071f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29750221-497e-4747-a9b8-12a0c2236eae (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e19f83b8-8c59-415c-a744-7473d46ab0ca (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e94aa8b1-74ed-46b7-94c5-53d5d5630be6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7d5dce0-f8a2-404d-9e87-e2235f5d3268 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd16a25c-67b6-ae6c-e053-6394a90aeee0 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4009c6cb-c183-2165-e063-6294a90aed78 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8278b4e-cca2-4880-8924-c8202ce084d6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f041e5f7-c138-4622-98bf-881f9a649a26 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.

    2. 2.5 hours

      Numeric value
      2.5
      Unit
      hours
      Source records
      53

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 53 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2f4e117-0318-4bbd-aaa7-fab803714f21 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a3fa9c69-4baf-44f5-bac4-a19c34b0e1cb (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ac00d59-bb80-4530-afe7-90e04a2130b2 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22ea819a-2aaa-44e0-a350-258541b11220 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cfd52c0c-a7c2-e23d-e053-2a95a90abbd1 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9833a1b8-f530-4a06-bc77-7d11b6e94c65 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f4889d1-1387-4c90-9b76-00beda3c1683 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac897a5a-677b-4a6e-abb1-b810470200fc (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:99cc8f5f-b947-4ddc-99b6-1e4cef09b717 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32c3be66-5398-425c-ac65-e57ba819bb43 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ebccdb33-2b3c-4071-9765-8d95bcbc9b5f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0e4eb26-6733-4df6-bb3c-86bf4d976f42 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c993e3c-ee52-45a7-be39-60eaac7a1092 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dd09a0d-a782-1d6d-a552-b71e5bcbf2fe (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e13b111a-25b7-4fdd-a102-30f2996722f3 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf77e63c-a62a-43fc-8705-0558925e04e8 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89105a78-badb-469e-966e-195fa3a53f0a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2353d09-3cb4-486e-8ae7-29339c1ba76b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d9a2492-d914-f87b-e063-6394a90a38c6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8288ccd-6c66-415e-a06b-758971afe9a0 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b88c338-c0b7-4c08-bef6-a4ffc2f25df7 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49adcfc8-3b1d-7f7e-e063-6294a90a361e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5460dbf8-b30d-db94-e063-6394a90a5553 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01c0d3d3-2373-a1b7-822a-80a66291a248 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:acc8f9f6-ceb6-0505-8f11-fd7e1f105af3 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f39499a-98cf-4d13-9b07-ccb5c22e43c8 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:047c67cd-7a63-49c9-b100-71651d3537ba (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59084f59-9a9b-49f0-a9f4-27f3eab9a228 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52830423-0430-410e-93af-169dc11b3565 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6b4486f-e847-64ee-e053-2995a90a855a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45de30ce-959f-4e2e-a974-6f90568139c9 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8d0b2b22-e1df-4ad5-92e6-f9a369108e4b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b14bd166-9f53-4f2e-be05-c447af04ef69 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:615dfd5c-125a-40e2-a6da-afacde305282 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eeb18068-75c8-42d0-a006-1b134648333f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da31fbeb-3781-5e75-e053-2a95a90adb73 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a2cf456-58c5-c26d-e063-6294a90a0b24 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9678a98e-4aab-4d87-b5e1-37c3109e378e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30caf3b3-8c1b-268e-e063-6294a90a3c8a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19cf46b5-d8dc-44cb-83d6-bacea0870dbe (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:433ac98f-ac22-44ad-a8b4-5db5560b9d0f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63b7eba3-6dea-4d89-bc42-7e965ae9795d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:146c853c-99a8-4bf3-b1e3-be6876abe6ff (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:308d2fdc-6136-4e75-95d3-342497add66c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e97c1ba-8171-4707-98ee-61afed75daac (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d127a0b-b182-4c8a-91a3-311cc936fd4c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fd932fb-033c-4774-ac09-c823db8f9739 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee3e9813-a738-46d1-9c05-c931aee1495c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9ba9023-0c3f-4c9b-ba8e-d39d23bf35d6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a42f3479-f2c2-8214-d547-c5cae9bfed1e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60c27d35-7349-4fc6-86ad-70fffdbe3e08 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bbc81e5-ad3e-496b-908f-e6f500f6ad7e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d24e0cda-a22f-404f-b861-f85090cef099 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Elimination Metabolism Tizanidine has a half-life of approximately 2.5 hours (CV=33%).

  3. Projected row 1523

    Medicine slug
    tizanidine
    Compared field
    tMax
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    125
    Source count
    108
    Agreement rate
    0.601852
    Recorded readings

    1. 1.0 hours

      Numeric value
      1
      Unit
      hours
      Source records
      65

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 65 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2f4e117-0318-4bbd-aaa7-fab803714f21 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules – Fasting • Tmax was 1.0 hours after dosing • T ½ was approximately 2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc96ee6-c99b-7283-e053-2a95a90ad14d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f87e30ce-a60a-41e3-b5d6-7e2966143961 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22ea819a-2aaa-44e0-a350-258541b11220 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules – Fasting • T max was 1.0 hours after dosing • T ½ was approximately 2 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f460275-565f-4737-a3df-bf80b9acc268 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cfd52c0c-a7c2-e23d-e053-2a95a90abbd1 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting Tmax was 1.0 hours after dosing T ½ was approximately 2 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26f8f233-5dc2-0013-e063-6394a90ab0f5 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81501cb1-0a76-4bd0-8eee-dbd1e4a0b69f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4659df31-8b89-4eff-9d86-7b7e38de416b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a91884a-39c3-f7ac-e063-6394a90ade14 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:73269d77-16b5-4787-9a7d-1b8688623436 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f4889d1-1387-4c90-9b76-00beda3c1683 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting T max was 1.0 hours after dosing T ½ was approximately 2 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac897a5a-677b-4a6e-abb1-b810470200fc (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting Tmax was 1.0 hours after dosing T ½ was approximately 2 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:99cc8f5f-b947-4ddc-99b6-1e4cef09b717 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting ● T max was 1.0 hours after dosing ● T ½ was approximately 2 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb8b01b3-bcec-4762-9d67-0db018ef6b22 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03fa03a6-fd05-4f17-872a-3c123330935d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae9b6808-632f-4204-8581-bf146dcab69f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32c3be66-5398-425c-ac65-e57ba819bb43 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting • Tmax was 1.0 hours after dosing • T ½ was approximately 2 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b353cdb8-75fa-7e3c-e053-2a95a90ada58 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:043d9e51-bfa2-4add-9058-5ece332f7e99 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ebccdb33-2b3c-4071-9765-8d95bcbc9b5f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting • T max was 1.0 hours after dosing • T ½ was approximately 2 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c993e3c-ee52-45a7-be39-60eaac7a1092 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting • Tmax was 1.0 hours after dosing • T ½ was approximately 2 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72f25135-1333-4e52-83f5-7df7d90e68bb (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea242c7d-b101-4197-8e65-b2b079e3b2b6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8288ccd-6c66-415e-a06b-758971afe9a0 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules – Fasting • Tmax was 1.0 hours after dosing • T ½ was approximately 2 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0bdc188d-b895-acbc-e063-6294a90acd68 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd3bf952-50b1-4d50-9073-57fd6888053b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20424d92-5ca1-4114-bc51-1f07c3bed6be (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76dc85bd-3cde-4940-a99b-663b70bf9f54 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d2961d1c-5de2-0a2b-e053-2995a90ad2fc (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f39499a-98cf-4d13-9b07-ccb5c22e43c8 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting T max was 1.0 hours after dosing T ½ was approximately 2 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14bcfbac-8f6a-42af-b3a4-ba10d99f2468 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59084f59-9a9b-49f0-a9f4-27f3eab9a228 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting Tmax was 1.0 hours after dosing T ½ was approximately 2 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f8a5b21-4adb-4f2c-91ae-bc33c3810752 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff7a82ea-c03c-44f6-9b15-468cb8d15a9c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52830423-0430-410e-93af-169dc11b3565 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting T max was 1.0 hours after dosing T ½ was approximately 2 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6b4486f-e847-64ee-e053-2995a90a855a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting Tmax was 1.0 hours after dosing T ½ was approximately 2 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45de30ce-959f-4e2e-a974-6f90568139c9 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting Tmax was 1.0 hours after dosing T ½ was approximately 2 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8d0b2b22-e1df-4ad5-92e6-f9a369108e4b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting • T max was 1.0 hours after dosing • T ½ was approximately 2 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5b7b4721-e6fa-4586-ac40-091ad363ee85 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a5b6614-038f-4e5b-9543-0497872c7882 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af73c6ab-6c1c-94d1-e053-2a95a90a4e3c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef7673f4-e0c1-4d79-af36-2f2ed2cc28f7 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da31fbeb-3781-5e75-e053-2a95a90adb73 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting Tmax was 1.0 hours after dosing T ½ was approximately 2 hours.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25db7cc0-604c-3d6b-e063-6394a90a337f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19cf46b5-d8dc-44cb-83d6-bacea0870dbe (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting T max was 1.0 hours after dosing T ½ was approximately 2 hours.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51da17a0-63d2-44fb-a79d-a3bee862e028 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e13292b0-9858-4405-8787-a2392d1b6d75 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:433ac98f-ac22-44ad-a8b4-5db5560b9d0f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting T max was 1.0 hours after dosing T ½ was approximately 2 hours.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fdf4f09d-4537-a438-e053-6394a90a573d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:146c853c-99a8-4bf3-b1e3-be6876abe6ff (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting T max was 1.0 hours after dosing T ½ was approximately 2 hours.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07b8db58-d037-477e-a62f-025e8a5afcb4 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3b8d863-d13d-467c-97bf-5db9708036db (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6439a7ef-1b22-4fa1-9be3-eedd3cd24191 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c46c7aa3-69db-82dc-e053-2995a90ac251 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d127a0b-b182-4c8a-91a3-311cc936fd4c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting T max was 1.0 hours after dosing T ½ was approximately 2 hours.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f32f399f-42af-f0ba-e053-2a95a90a8c2e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fefe8332-32eb-4b81-978f-b23b334d7d57 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6dd9946f-b2a4-1732-e053-2a91aa0a648f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a42f3479-f2c2-8214-d547-c5cae9bfed1e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting Tmax was 1.0 hours after dosing T ½ was approximately 2 hours.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd16a25c-67b6-ae6c-e053-6394a90aeee0 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4009c6cb-c183-2165-e063-6294a90aed78 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60c27d35-7349-4fc6-86ad-70fffdbe3e08 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting T max was 1.0 hours after dosing T 1/2 was approximately 2 hours.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bbc81e5-ad3e-496b-908f-e6f500f6ad7e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting Tmax was 1.0 hours after dosing T ½ was approximately 2 hours.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f041e5f7-c138-4622-98bf-881f9a649a26 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1.0 hours after dosing with a half-life of approximately 2 hours.

    2. 1 hours

      Numeric value
      1
      Unit
      hours
      Source records
      43

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 43 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a7b9b9a-9bf9-0b37-e063-6294a90a1c39 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:247ae1f4-6ec8-4e34-aae4-13495d8f64e5 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67b2af93-92c9-4c33-8fa0-548bfcc9c538 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ac00d59-bb80-4530-afe7-90e04a2130b2 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24d8b33f-d1fb-4b4a-afbe-e2e7134dce29 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eed74219-9d4a-fecd-1bb9-ad6c01ad3e9d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c2bdad9-74a5-8508-e063-6294a90aac7f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a275f9-de6b-ee63-e063-6294a90aba28 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82084f4e-00d0-c298-c13a-88a6c0860b02 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe2f5064-0b7c-d03d-e053-6294a90a9604 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0e4eb26-6733-4df6-bb3c-86bf4d976f42 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dd09a0d-a782-1d6d-a552-b71e5bcbf2fe (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting T max was 1 hour after dosing T ½ was approximately 2 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89105a78-badb-469e-966e-195fa3a53f0a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d9a2492-d914-f87b-e063-6394a90a38c6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180985f0-3fbd-4868-a826-b84101618a03 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:21b7c8a8-ee07-a204-e063-6394a90a285b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01c0d3d3-2373-a1b7-822a-80a66291a248 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:acc8f9f6-ceb6-0505-8f11-fd7e1f105af3 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting • T max was 1 hours after dosing • T ½ was approximately 2 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b694225c-1fa9-4726-89a6-fd3f87084248 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc90292-c6bf-2d96-e053-2995a90abf00 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3670f9e3-988d-48e6-9df0-d403d699e08a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b254a0f4-efb1-4874-ae45-1dc5fe316964 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59d83e3a-5e44-d8d0-e063-6294a90aa65a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eeb18068-75c8-42d0-a006-1b134648333f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9bcc7f09-d2b5-4602-aaf3-5410b55ce275 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30caf3b3-8c1b-268e-e063-6294a90a3c8a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63b7eba3-6dea-4d89-bc42-7e965ae9795d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7470959-8943-215b-e053-2a95a90a7878 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81385ce2-1d82-4987-8e18-83c823e10b99 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee3e9813-a738-46d1-9c05-c931aee1495c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules – Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ade0c7-4bf0-54d4-e063-6294a90a8b17 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:492c99bd-2cd0-43be-bd70-800b739b7e83 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b68a9f81-7138-48cf-b987-b8d284e8105a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2788942d-87fa-e514-e063-6294a90a0971 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9ba9023-0c3f-4c9b-ba8e-d39d23bf35d6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules -Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26cffb1f-21a0-017f-e063-6394a90afb1a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58c10b87-004e-4d2d-b5c1-b353c2cd071f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29750221-497e-4747-a9b8-12a0c2236eae (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e19f83b8-8c59-415c-a744-7473d46ab0ca (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e94aa8b1-74ed-46b7-94c5-53d5d5630be6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7d5dce0-f8a2-404d-9e87-e2235f5d3268 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8278b4e-cca2-4880-8924-c8202ce084d6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Following oral administration of either the tablet or capsule (in the fasted state), peak plasma concentrations of tizanidine occurred 1 hours after dosing with a half-life of approximately 2 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d24e0cda-a22f-404f-b861-f85090cef099 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tablets or Capsules - Fasting T max was 1 hours after dosing T ½ was approximately 2 hours.

  4. Projected row 1524

    Medicine slug
    tizanidine
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    125
    Source count
    124
    Agreement rate
    1
    Recorded readings

    1. 2.4 L/kg

      Numeric value
      2.4
      Unit
      L/kg
      Source records
      124

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 124 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a7b9b9a-9bf9-0b37-e063-6294a90a1c39 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2f4e117-0318-4bbd-aaa7-fab803714f21 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine Tablets and Tizanidine Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:247ae1f4-6ec8-4e34-aae4-13495d8f64e5 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67b2af93-92c9-4c33-8fa0-548bfcc9c538 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc96ee6-c99b-7283-e053-2a95a90ad14d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f87e30ce-a60a-41e3-b5d6-7e2966143961 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a3fa9c69-4baf-44f5-bac4-a19c34b0e1cb (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ac00d59-bb80-4530-afe7-90e04a2130b2 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine Tablets and Zanaflex Capsules (2 mg x 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22ea819a-2aaa-44e0-a350-258541b11220 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine Tablets and Tizanidine Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24d8b33f-d1fb-4b4a-afbe-e2e7134dce29 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f460275-565f-4737-a3df-bf80b9acc268 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cfd52c0c-a7c2-e23d-e053-2a95a90abbd1 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Extent of absorption was increased approximately 30% Figure 1: Mean Tizanidine Concentration vs. Time Profiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9833a1b8-f530-4a06-bc77-7d11b6e94c65 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        izanidine Tablets and Tizanidine Capsules (2 X 4 mg) Under Fasting and Fed Conditions Distribution ​Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV=21%) following intravenous administration in healthy adult volunteers.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26f8f233-5dc2-0013-e063-6394a90ab0f5 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81501cb1-0a76-4bd0-8eee-dbd1e4a0b69f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eed74219-9d4a-fecd-1bb9-ad6c01ad3e9d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4659df31-8b89-4eff-9d86-7b7e38de416b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a91884a-39c3-f7ac-e063-6394a90ade14 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:73269d77-16b5-4787-9a7d-1b8688623436 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c2bdad9-74a5-8508-e063-6294a90aac7f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f4889d1-1387-4c90-9b76-00beda3c1683 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        or Tizanidine Tablets and Zanaflex Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac897a5a-677b-4a6e-abb1-b810470200fc (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Extent of absorption was increased approximately 30% Figure 1: Mean Tizanidine Concentration vs. Time Profiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a275f9-de6b-ee63-e063-6294a90aba28 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:99cc8f5f-b947-4ddc-99b6-1e4cef09b717 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb8b01b3-bcec-4762-9d67-0db018ef6b22 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82084f4e-00d0-c298-c13a-88a6c0860b02 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe2f5064-0b7c-d03d-e053-6294a90a9604 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03fa03a6-fd05-4f17-872a-3c123330935d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae9b6808-632f-4204-8581-bf146dcab69f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32c3be66-5398-425c-ac65-e57ba819bb43 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b353cdb8-75fa-7e3c-e053-2a95a90ada58 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:043d9e51-bfa2-4add-9058-5ece332f7e99 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ebccdb33-2b3c-4071-9765-8d95bcbc9b5f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine Tablets and Tizanidine Capsules (2 X 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0e4eb26-6733-4df6-bb3c-86bf4d976f42 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c993e3c-ee52-45a7-be39-60eaac7a1092 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dd09a0d-a782-1d6d-a552-b71e5bcbf2fe (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e13b111a-25b7-4fdd-a102-30f2996722f3 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72f25135-1333-4e52-83f5-7df7d90e68bb (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea242c7d-b101-4197-8e65-b2b079e3b2b6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf77e63c-a62a-43fc-8705-0558925e04e8 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89105a78-badb-469e-966e-195fa3a53f0a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        zanidine Tablets and Tizanidine Capsules (2 mg x 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2353d09-3cb4-486e-8ae7-29339c1ba76b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d9a2492-d914-f87b-e063-6394a90a38c6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        zanidine Tablets and Tizanidine Capsules (2 mg x 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8288ccd-6c66-415e-a06b-758971afe9a0 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine Tablets and Tizanidine Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0bdc188d-b895-acbc-e063-6294a90acd68 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180985f0-3fbd-4868-a826-b84101618a03 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:21b7c8a8-ee07-a204-e063-6394a90a285b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b88c338-c0b7-4c08-bef6-a4ffc2f25df7 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49adcfc8-3b1d-7f7e-e063-6294a90a361e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5460dbf8-b30d-db94-e063-6394a90a5553 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        d Tizanidine Capsules (2 X 4 mg) Under Fasted and Fed Conditions ["Image Description"] Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd3bf952-50b1-4d50-9073-57fd6888053b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20424d92-5ca1-4114-bc51-1f07c3bed6be (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76dc85bd-3cde-4940-a99b-663b70bf9f54 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d2961d1c-5de2-0a2b-e053-2995a90ad2fc (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01c0d3d3-2373-a1b7-822a-80a66291a248 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:acc8f9f6-ceb6-0505-8f11-fd7e1f105af3 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles for Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f39499a-98cf-4d13-9b07-ccb5c22e43c8 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine Tablets and Tizanidine Capsules (2 X 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b694225c-1fa9-4726-89a6-fd3f87084248 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:047c67cd-7a63-49c9-b100-71651d3537ba (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14bcfbac-8f6a-42af-b3a4-ba10d99f2468 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59084f59-9a9b-49f0-a9f4-27f3eab9a228 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Extent of absorption was increased approximately 30% Figure 1: Mean Tizanidine Concentration vs. Time Profiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc90292-c6bf-2d96-e053-2995a90abf00 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3670f9e3-988d-48e6-9df0-d403d699e08a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f8a5b21-4adb-4f2c-91ae-bc33c3810752 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff7a82ea-c03c-44f6-9b15-468cb8d15a9c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b254a0f4-efb1-4874-ae45-1dc5fe316964 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52830423-0430-410e-93af-169dc11b3565 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6b4486f-e847-64ee-e053-2995a90a855a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Extent of absorption was increased approximately 30% Figure 1: Mean Tizanidine Concentration vs. Time Profiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45de30ce-959f-4e2e-a974-6f90568139c9 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Extent of absorption was increased approximately 30% Figure 1: Mean Tizanidine Concentration vs. Time Profiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8d0b2b22-e1df-4ad5-92e6-f9a369108e4b (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59d83e3a-5e44-d8d0-e063-6294a90aa65a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b14bd166-9f53-4f2e-be05-c447af04ef69 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5b7b4721-e6fa-4586-ac40-091ad363ee85 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a5b6614-038f-4e5b-9543-0497872c7882 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af73c6ab-6c1c-94d1-e053-2a95a90a4e3c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef7673f4-e0c1-4d79-af36-2f2ed2cc28f7 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:615dfd5c-125a-40e2-a6da-afacde305282 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eeb18068-75c8-42d0-a006-1b134648333f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da31fbeb-3781-5e75-e053-2a95a90adb73 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Extent of absorption was increased approximately 30% Figure 1: Mean Tizanidine Concentration vs. Time Profiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a2cf456-58c5-c26d-e063-6294a90a0b24 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        izanidine Tablets and Tizanidine Capsules (2 X 4 mg) Under Fasting and Fed Conditions Distribution ​Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV=21%) following intravenous administration in healthy adult volunteers.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25db7cc0-604c-3d6b-e063-6394a90a337f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9bcc7f09-d2b5-4602-aaf3-5410b55ce275 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9678a98e-4aab-4d87-b5e1-37c3109e378e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30caf3b3-8c1b-268e-e063-6294a90a3c8a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        zanidine Tablets and Tizanidine Capsules (2 mg x 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19cf46b5-d8dc-44cb-83d6-bacea0870dbe (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51da17a0-63d2-44fb-a79d-a3bee862e028 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e13292b0-9858-4405-8787-a2392d1b6d75 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:433ac98f-ac22-44ad-a8b4-5db5560b9d0f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63b7eba3-6dea-4d89-bc42-7e965ae9795d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine Tablets and Zanaflex Capsules (2 mg x 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fdf4f09d-4537-a438-e053-6394a90a573d (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:146c853c-99a8-4bf3-b1e3-be6876abe6ff (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07b8db58-d037-477e-a62f-025e8a5afcb4 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:308d2fdc-6136-4e75-95d3-342497add66c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e97c1ba-8171-4707-98ee-61afed75daac (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7470959-8943-215b-e053-2a95a90a7878 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3b8d863-d13d-467c-97bf-5db9708036db (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81385ce2-1d82-4987-8e18-83c823e10b99 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6439a7ef-1b22-4fa1-9be3-eedd3cd24191 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c46c7aa3-69db-82dc-e053-2995a90ac251 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d127a0b-b182-4c8a-91a3-311cc936fd4c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine Tablets and Tizanidine Capsules (2 X 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f32f399f-42af-f0ba-e053-2a95a90a8c2e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fefe8332-32eb-4b81-978f-b23b334d7d57 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fd932fb-033c-4774-ac09-c823db8f9739 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee3e9813-a738-46d1-9c05-c931aee1495c (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        zanidine Hydrochloride Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ade0c7-4bf0-54d4-e063-6294a90a8b17 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6dd9946f-b2a4-1732-e053-2a91aa0a648f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:492c99bd-2cd0-43be-bd70-800b739b7e83 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b68a9f81-7138-48cf-b987-b8d284e8105a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2788942d-87fa-e514-e063-6294a90a0971 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9ba9023-0c3f-4c9b-ba8e-d39d23bf35d6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        zanidine Tablets and Tizanidine Capsules (2 mg x 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26cffb1f-21a0-017f-e063-6394a90afb1a (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58c10b87-004e-4d2d-b5c1-b353c2cd071f (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29750221-497e-4747-a9b8-12a0c2236eae (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e19f83b8-8c59-415c-a744-7473d46ab0ca (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e94aa8b1-74ed-46b7-94c5-53d5d5630be6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a42f3479-f2c2-8214-d547-c5cae9bfed1e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Extent of absorption was increased approximately 30% Figure 1: Mean Tizanidine Concentration vs. Time Profiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7d5dce0-f8a2-404d-9e87-e2235f5d3268 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd16a25c-67b6-ae6c-e053-6394a90aeee0 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4009c6cb-c183-2165-e063-6294a90aed78 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8278b4e-cca2-4880-8924-c8202ce084d6 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60c27d35-7349-4fc6-86ad-70fffdbe3e08 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Profiles For Zanaflex Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bbc81e5-ad3e-496b-908f-e6f500f6ad7e (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Extent of absorption was increased approximately 30% Figure 1: Mean Tizanidine Concentration vs. Time Profiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f041e5f7-c138-4622-98bf-881f9a649a26 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d24e0cda-a22f-404f-b861-f85090cef099 (opens source in a new tab)

        Tizanidine label

        Version not recorded · Effective date not recorded

        rofiles For Tizanidine Tablets and Capsules (2 × 4 mg) Under Fasted and Fed Conditions Distribution Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers.

  5. Projected row 1525

    Medicine slug
    tobramycin
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    58
    Source count
    30
    Agreement rate
    0.566667
    Recorded readings

    1. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      17

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 17 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c4751a4f-c9c1-60c5-e053-2995a90aeba9 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c37c251f-92e9-40f0-8b0c-00d42875d776 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a5cecd6-aa65-42d2-b15a-06b4fcebcc0f (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum elimination half-life in patients with normal renal function is 2 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02b48684-168c-4cd9-8375-794206eff23e (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da1e5afd-d707-4af1-8935-8195ba6d769f (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac8134d9-a726-4508-b8b9-a536ef17243d (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed254eec-10f4-425a-895b-66e325b7bf69 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c5a005b0-7b6f-4e30-df92-9a20b1ca66a1 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:645d34d9-275d-428e-863d-ae15ad009c44 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38219f34-4859-428f-9ec1-06ead7604211 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55d09ffd-4f32-8aeb-3904-8a17db635e3a (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9897444-71f6-42af-9b71-4aa77829ade0 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dad13445-f591-4829-96f9-1598ba03dff8 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a384641c-04e3-4ab5-b152-7408cd07b64d (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6dd9460-b030-479a-b3e3-03606e6fcad1 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d62ff359-912b-4be1-9fc2-2dde8777eefb (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum elimination half-life in patients with normal renal function is 2 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b50d1b5-ea8a-5844-358a-493f1965c07f (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The serum half-life in normal individuals is 2 hours.

    2. 3 hours

      Numeric value
      3
      Unit
      hours
      Source records
      12

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 12 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2f8bf02-57f8-4d34-937a-32411fc6bfba (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5563e8af-c6c9-42a2-974d-7d364a47f00a (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8205898-0162-4e6c-bcf1-87cb074ab9ae (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15f9c0cd-7dbf-4a91-9961-14f1dd000343 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d8b7b6c-3072-48e9-87c8-51160b9df9bc (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c5f65e5b-c851-45da-a0e8-215d9a4e6ad3 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a3c3871-1d3a-44d6-8be3-526b30123ef7 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:845e3328-fffa-44eb-b78a-3607c05fdd55 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0aa5859e-cd80-49c0-881b-47f39d1f1d01 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd871ae7-9083-4e57-aacb-f584c1390db9 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7803ac83-1250-451b-8ad8-2c0a343c3031 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c452e428-0d8f-4f35-b98f-5aa3b814cb49 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        Excretion The elimination half-life of tobramycin from serum is approximately 2 and 3 hours after intravenous (IV) administration and inhalation, respectively.

    3. 4.4 hours

      Numeric value
      4.4
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cd3d47b-025f-4705-9daf-cf07725ec223 (opens source in a new tab)

        Tobramycin label

        Version not recorded · Effective date not recorded

        The elimination half-life following the inhalation of BETHKIS is approximately 4.4 hours.

  6. Projected row 1526

    Medicine slug
    tocilizumab
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    4
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 80%

      Numeric value
      80
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13 (opens source in a new tab)

        Tocilizumab label

        Version not recorded · Effective date not recorded

        The bioavailability for the subcutaneous formulation was 80%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:581c288f-8015-40ef-a4c3-683c96db193d (opens source in a new tab)

        Tocilizumab label

        Version not recorded · Effective date not recorded

        The bioavailability for the subcutaneous formulation was 80%.

  7. Projected row 1527

    Medicine slug
    tocilizumab
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    4
    Source count
    4
    Agreement rate
    1
    Recorded readings

    1. 21.5 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ab3207a-ebfe-4565-9ce5-3a1538815c83 (opens source in a new tab)

        Tocilizumab label

        Version not recorded · Effective date not recorded

        At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13 (opens source in a new tab)

        Tocilizumab label

        Version not recorded · Effective date not recorded

        At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:581c288f-8015-40ef-a4c3-683c96db193d (opens source in a new tab)

        Tocilizumab label

        Version not recorded · Effective date not recorded

        At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00529b23-850a-42b9-a152-125a95b5242c (opens source in a new tab)

        Tocilizumab label

        Version not recorded · Effective date not recorded

        At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates.

  8. Projected row 1528

    Medicine slug
    tocilizumab-aazg
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    3
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 80%

      Numeric value
      80
      Unit
      %
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87ac5047-4f2b-4571-a8a8-32e08865f379 (opens source in a new tab)

        Tocilizumab-Aazg label

        Version not recorded · Effective date not recorded

        The bioavailability for the subcutaneous formulation was 80%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ad76441d-da59-47df-8d9d-2243005180f0 (opens source in a new tab)

        Tocilizumab-Aazg label

        Version not recorded · Effective date not recorded

        The bioavailability for the subcutaneous formulation was 80%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e400bbe6-43c5-4de6-82b9-cb44ce3cd906 (opens source in a new tab)

        Tocilizumab-Aazg label

        Version not recorded · Effective date not recorded

        The bioavailability for the subcutaneous formulation was 80%.

  9. Projected row 1529

    Medicine slug
    tocilizumab-aazg
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    3
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 21.5 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87ac5047-4f2b-4571-a8a8-32e08865f379 (opens source in a new tab)

        Tocilizumab-Aazg label

        Version not recorded · Effective date not recorded

        At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ad76441d-da59-47df-8d9d-2243005180f0 (opens source in a new tab)

        Tocilizumab-Aazg label

        Version not recorded · Effective date not recorded

        At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e400bbe6-43c5-4de6-82b9-cb44ce3cd906 (opens source in a new tab)

        Tocilizumab-Aazg label

        Version not recorded · Effective date not recorded

        At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates.

  10. Projected row 1530

    Medicine slug
    tofacitinib
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    29
    Source count
    28
    Agreement rate
    1
    Recorded readings

    1. 74%

      Numeric value
      74
      Unit
      %
      Source records
      28

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 28 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:253635c8-1ea7-41ba-b216-dea5e3305c47 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58b94979-55ad-839a-e063-6294a90ad812 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        41 (40) 3.10 (54) 1.07 (69) 3.11 (43) T max (hours) 1.0 (0.5 to 14.0 b ) 0.8 (0.5 to 14.0 b ) 4.0 (3.0 to 4.0) 4.0 (2.0 to 4.0) Absorption Tofacitinib Tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:024bb9f2-8c26-4d9d-a33b-eb3c0a7c59ed (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        PK Parameters a (CV%) Tofacitinib Extended-Release Tablets Dosing Regimen 11 mg Once Daily 22 mg Once Daily AUC 24 (ng.hr/mL) 269.0 (18) 596.6 (19) C max (ng/mL) 38.2 (15) 83.8 (25) C min (ng/mL) 1.07 (69) 3.11 (43) T max (hours) 4.0 (3.0 to 4.0) 4.0 (2.0 to 4.0) Absorption Tofacitinib tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:141ab3eb-982b-4242-89db-6ddce5be0c40 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        AUC 24 (ng.hr/mL) 269.0 (18) 596.6 (19) C max (ng/mL) 38.2 (15) 83.8 (25) C min (ng/mL) 1.07 (69) 3.11 (43) T max (hours) 4.0 (3.0 to 4.0) 4.0 (2.0 to 4.0) Absorption XELJANZ The absolute oral bioavailability of XELJANZ is 74%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a764a133-b870-4514-bbee-24d43f8cb7fd (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib The absolute oral bioavailability of tofacitinib is 74%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:327f6b60-1a5d-49e6-acff-18603d0ee9d0 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib The absolute oral bioavailability of tofacitinib is 74%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd62a2b8-300b-d92b-7b27-a30eaa68fdd3 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption XELJANZ The absolute oral bioavailability of XELJANZ is 74%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58f22c41-87d2-e745-e063-6394a90a962e (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib Tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf74ba2f-afc5-4baa-8594-979c889a5831 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        vening dose which was administered 12 hours after the morning dose of twice-daily XELJANZ. ) 0.8 (0.5 to 14.0 ) 4.0 (3.0 to 4.0) 4.0 (2.0 to 4.0) Absorption XELJANZ The absolute oral bioavailability of XELJANZ is 74%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:21a89264-8047-40ac-8b10-fa6461072509 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib tablets The absolute oral bioavailability of tofacitinib is 74%.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffa6819b-23a4-478b-8fb7-cc90e8142fc5 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib Tablets The absolute oral bioavailability of tofacitinib tablets are 74%.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5751321a-c904-44ae-e063-6394a90a2654 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinibtablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0160e3d-63ea-75fb-4b88-fe3d6a6ce030 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib Tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e54b186f-e42a-4477-939c-8dd331045fbe (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        41 (40) 3.10 (54) 1.07 (69) 3.11 (43) T max (hours) 1.0 (0.5 to 14.0 b ) 0.8 (0.5 to 14.0 b ) 4.0 (3.0 to 4.0) 4.0 (2.0 to 4.0) Absorption Tofacitinib Tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:68e3d6b2-7838-4d2d-a417-09d919b43e13 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        vening dose which was administered 12 hours after the morning dose of twice-daily XELJANZ. ) 0.8 (0.5 to 14.0 ) 4.0 (3.0 to 4.0) 4.0 (2.0 to 4.0) Absorption XELJANZ The absolute oral bioavailability of XELJANZ is 74%.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11d08738-efa3-4474-8eda-812bc04adfbb (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        AUC 24 (ng.hr/mL) 269.0 (18) 596.6 (19) C max (ng/mL) 38.2 (15) 83.8 (25) C min (ng/mL) 1.07 (69) 3.11 (43) T max (hours) 4.0 (3.0 to 4.0) 4.0 (2.0 to 4.0) Absorption XELJANZ The absolute oral bioavailability of XELJANZ is 74%.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5502f252-2b39-2cfd-e063-6394a90a8a48 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption XELJANZ The absolute oral bioavailability of XELJANZ is 74%.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9cf18a9-e825-49ac-b080-68957c0e79ae (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib Tablets The absolute oral bioavailability of tofacitinib is 74%.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50962b08-99dd-ae73-e063-6394a90ad1eb (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib Tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5617a652-a78e-74b1-e063-6394a90a31c7 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption XELJANZ The absolute oral bioavailability of XELJANZ is 74%.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cd1b61bf-de03-4198-89f6-f3952b79d2c2 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption XELJANZ The absolute oral bioavailability of XELJANZ is 74%.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b654f0d-7705-4880-9e9d-ad3a51e56b56 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d4f5cfa-35a8-1458-a609-f6b417946abb (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib Tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2726c2b0-c763-4635-ac6b-4334c3a5a8bc (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df24e90d-4b2c-4f9d-a1d6-fcb1ab00606f (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        CV = Coefficient of variation. a Values represent the geometric mean, except T max, for which is the median (range) is shown. b Values beyond 12 hours were after the evening dose which was administered 12 hours after the morning dose of twice-daily tofacitinib tablets Absorption Tofacitinib Tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:576722e5-6639-452d-a5c3-33a064f19481 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption Tofacitinib The absolute oral bioavailability of tofacitinib is 74%.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c963c610-52e5-43ab-aac6-3f7e5341b764 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        AUC 24 (ng.hr/mL) 263.4 (15) 539.6 (22) Cmax (ng/mL) 42.7 (26) 84.7 (18) Cmin (ng/mL) 1.41 (40) 3.10 (54) Tmax (hours) 1.0 (0.5 to14.0 Values beyond 12 hours were after the evening dose which was administered 12 hours after the morning dose of twice-daily tofacitinib tablets. ) 0.8 (0.5 to 14.0 ) Absorption Tofacitinib Tablets The absolute oral bioavailability of tofacitinib tablets is 74%.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e68680e5-0328-4e66-b8bb-4af126221ec7 (opens source in a new tab)

        Tofacitinib label

        Version not recorded · Effective date not recorded

        Absorption XELJANZ The absolute oral bioavailability of XELJANZ is 74%.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=1520

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy